Treatment strategies for neuroendocrine liver metastases: a systematic review

Muttillo, Edoardo Maria; Mazzarella, Gennaro; Picardi, Biagio; Rossi, Stefano; Cinelli, Lorenzo; Diana, Michèle; Baiocchini, Andrea; Felli, Eric; Pessaux, Patrick; Felli, Emanuele; Muttillo, Irnerio Angelo

doi:10.1016/j.hpb.2022.06.009

Cited by 12 publications

(9 citation statements)

References 67 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Second, our research participants were Chinese patients with g-NENs; therefore, there is a certain limitation to the universality and extrapolation of our results. Third, the liver is the main site of g-NEN metastases as recently published [40]. The primary endpoint of this study was OS and the data on liver metastases was lacking.…”

Section: No Association Between Bmi and Gastric Cardiamentioning

confidence: 95%

Defining the impact of platelet-to-lymphocyte ratio on patient survival with gastric neuroendocrine neoplasm: a retrospective cohort analysis

Liang

Liu

et al. 2022

World J Surg Onc

View full text Add to dashboard Cite

Background Gastric neuroendocrine neoplasm (g-NEN) is a rare but heterogeneous neoplasm, with an increasing incidence yearly. Conventional prognostic markers of g-NEN remain limited which could only be detected after surgery. There is an urgent need to explore new prognostic markers for g-NEN patients. This study aimed to investigate the prognostic value of platelet-to-lymphocyte, ratio (PLR) and the association between PLR and body mass index (BMI) in patients with gastric neuroendocrine neoplasms (g-NEN). Methods A retrospective cohort of patients with g-NEN from January 2001 through June 2016 was examined. The prognostic significance of PLR was determined by multiple regression analysis in different models. Stratified analysis was performed to examine the prognostic value of PLR at different BMI levels. Results In total, 238 patients were enrolled. Those with higher PLRs tended to undergo open surgery, had larger tumor sizes, were diagnosed more frequently with neuroendocrine carcinoma, and had higher tumor grades. PLR was significantly associated with the survival of patients with g-NEN. With PLR increased per standard deviation, the all-cause mortality risk of patients with g-NEN increased by 67%, 63%, and 54% in the crude (HR = 1.67, 95% CI 1.32–2.12, P < 0.001), minimally adjusted (HR = 1.63, 95% CI 1.28–2.08, P < 0.001), and fully adjusted (HR = 1.54, 95% CI 1.202–1.98, P = 0.001) models, respectively. Patients with higher PLR (quartile 4, ≥ 187) had a 1.8-fold increase in all-cause mortality risk compared with those with lower PLR (quartile 1–3, < 187). Furthermore, there was a significant interaction effect between BMI subgroups and PLR in predicting the survival of patients with g-NEN (PLR regarded as a continuous variable: all P for interaction < 0.05 in the crude, minimally adjusted, and fully adjusted models; PLR regarded as a categorical variable: P for interaction < 0.05 in the fully adjusted model). Patients with g-NEN with the characteristics of higher PLR (quartile 4, ≥ 187) and non-obesity (BMI < 25 kg/m2) had worse survival than others (P < 0.05). Conclusion The inflammation marker PLR has an independent prognostic value for patients with g-NENs, and high PLR combined with non-obesity increases the mortality risk of these patients.

show abstract

Section: No Association Between Bmi and Gastric Cardiamentioning

confidence: 95%

Defining the impact of platelet-to-lymphocyte ratio on patient survival with gastric neuroendocrine neoplasm: a retrospective cohort analysis

Liang

Liu

et al. 2022

World J Surg Onc

View full text Add to dashboard Cite

show abstract

“…Neuroendokrine Tumoren (NET) sind eine sehr heterogene Tumorentität mit in der Regel langsamem Wachstum, wobei bereits bei bis zu 40% der Fälle im Rahmen der Erstdiagnose und bei bis zu 70% im weiteren Verlauf der Erkrankung eine hepatische Metastasierung zu beobachten ist, die maßgeblich die Prognose beeinflusst [56,57,58]. In aktuellen Leitlinien wird die TARE als lokoregionäres Therapieverfahren bei Somatostatin-Rezeptor-positiven und -negativen NET empfohlen, wobei es kaum vergleichende Daten zu alternativen Verfahren wie beispielsweise der TACE gibt [59].…”

Section: Neuroendokrine Tumorenunclassified

Radioembolisation mit Harz- und Glas-Mikrosphären

Ilhan,

Stegger,

Ahmadzadehfar

2023

Angewandte Nuklearmedizin

View full text Add to dashboard Cite

“…NETs are rare neoplasms that are characterized by heterogenous biological behavior as well as typically slow progression [13 ▪ ]. NETs are classified according to their biological potential with low grade (G1) tumors having a Ki-67 index <2%, intermediate (G2) with Ki-67 3–20%, and high-grade with Ki-67 >20% [1,2].…”

Section: Gastroenteropancreatic Neuroendocrine Tumors With Hepatic Me...mentioning

confidence: 99%

Treating rare tumors with liver transplantation

Melehy,

Agopian

2023

Current Opinion in Organ Transplantation

View full text Add to dashboard Cite

Purpose of review The success of liver transplantation (LT) in treating unresectable hepatocellular carcinoma (HCC) has resulted in interest in LT for other oncologic conditions. Here, we discuss the role of LT for rare oncologic indications including metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs), hepatic epitheliod hemangioendothelioma (HEHE), fibrolamellar hepatocellular carcinoma (FLC), and hepatic angiosarcoma (HAS). Recent findings Conditions reviewed have been documented indications for LT in the available literature. We summarize the experience of LT for these indications and proposed management guidelines. Summary GEP-NETs with isolated metastases to the liver can be treated with LT with excellent long-term outcomes (10-year survival 88%) if strict selection criteria are used (low-intermediate grade, Ki-67% < 20%, complete resection of primary tumor, stable disease for 6 months, <50% hepatic involvement). HEHE is a rare hepatic tumor for which LT can be performed with reported 10-year survival around 70%. FLC is a distinct clinical entity to HCC and is optimally treated with surgical resection though experience with LT is described in observational series (5-year survival 50%, recurrence in 10%). HAS is a rapidly progressive tumor with a dismal prognosis with or without treatment, including LT.

show abstract

Treatment strategies for neuroendocrine liver metastases: a systematic review

Cited by 12 publications

References 67 publications

Defining the impact of platelet-to-lymphocyte ratio on patient survival with gastric neuroendocrine neoplasm: a retrospective cohort analysis

Defining the impact of platelet-to-lymphocyte ratio on patient survival with gastric neuroendocrine neoplasm: a retrospective cohort analysis

Radioembolisation mit Harz- und Glas-Mikrosphären

Treating rare tumors with liver transplantation

Contact Info

Product

Resources

About